Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antiemetics Drugs Market

Antiemetics Drugs Market Trends

Report ID: GMI10262
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Antiemetics Drugs Market Trends

Advancements in drug formulations also play a crucial role in shaping the market. Pharmaceutical companies are investing in research and development to innovate new formulations that offer improved efficacy, safety, and patient compliance.
From extended-release formulations to novel drug delivery systems, these advancements not only enhance treatment outcomes but also differentiate products in a competitive market landscape.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global antiemetics drugs industry was valued at USD 6.7 billion in 2023 and is anticipated to register 5.6% CAGR between 2024 and 2032, driven by growing availability of reimbursement and coverage for antiemetic drugs.

The chemotherapy induced nausea and vomiting (CINV) segment in the market accounted for USD 3.1 billion in 2023 primarily due to the high incidence of cancer and the critical need for effective management.

U.S. antiemetics drugs market is projected to reach USD 4.2 billion by 2032, driven by innovations in drug formulations and delivery systems.

Astellas Pharma Inc., Baxter International Inc., Cipla Limited, Eagle Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, GSK plc, Hikma Pharmaceuticals PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG, among others.